AAN 2012: Interview with Dr. Zigmond about Exercise and Parkinson's Disease Study [Podcast]

Article

In this interview, Michael Zigmond, PhD, previews his lecture to be given at this year's AAN Annual Meeting. Zigmond explains how he became involved with studying Parkinson's disease (PD), research with exercise and PD, and what his intentions are with helping to fight this disease.

Professor of Neurology

In this interview, Michael Zigmond, PhD, at theUniversity of Pittsburgh, discusses why he became involved with studying Parkinson’s disease and his research on exercise and Parkinson’s disease which he will be presenting at this year's AAN conference.

When asked about how he began his research in Parkinson's disease, Zigmond said, "I became interested in catecholamines, which includes dopamine and norepinephrine primarily, as a graduate student. There was evidence that they were affected by stress and I was interested in looking at the adaptive effects of stress."

It was upon collaborating with colleague when Zigmond explained how he "discovered that... physicial exercise was what we would call 'neuroprotective.' If you had animals exercise before you expose them to a toxin like 6-Hydroxydopamine, the effects of the toxin on the animals' behavior and on the dopamine neurons themselves was reduced."

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.